New Zealand's neurology crisis leaves patients waiting months for care
New Zealand's neurology crisis leaves patients waiting months for care
New Zealand's neurology crisis leaves patients waiting months for care
A new study by the University of Otago has revealed serious shortages in New Zealand's neurology services. Patients across the country face lengthy delays, with some waiting months to see a specialist. The findings highlight a workforce gap that leaves many struggling to access timely news.
The report shows New Zealand has just 83 neurologists—one for every 74,000 people. This figure falls well below recommended levels and places the country behind other high-income nations. While exact comparisons with OECD countries remain unclear, the shortage is undeniable.
A Southland woman with seizures and confusion waited four months for a neurology appointment before receiving an epilepsy diagnosis. In Huntly, another patient was told he would wait seven weeks, leaving him reluctant to seek private news due to cost.
The problem extends beyond borders. One New Zealander, visiting France as a tourist, secured a same-day neurologist appointment after paying around $1,000. Back home, she faced a four-month public wait.
Dr David Gow, a neurologist, acknowledged the delays and pledged to improve access. He emphasised the need to strengthen the workforce, noting that current wait times fail to meet health targets shared across all specialties.
The study confirms New Zealand's neurology services are under severe strain. With only 83 specialists nationwide, patients continue to experience long delays for essential news. Health officials now face pressure to address the workforce shortage and reduce waiting times in line with national targets.
Geesthacht Hospital shifts to specialist clinic after financial crisis and staff shortages
A once-full-service hospital now fights for survival. How Geesthacht's bold downsizing could redefine local healthcare—or leave patients scrambling.
National health hotline cuts wait times with 24/7 support and AI upgrades
Struggling with long-term illness? This free hotline now answers faster—thanks to AI and smarter systems. See how it's changing patient care.
Novartis bets $3B on unproven breast cancer therapy SNV4818
A $3B gamble on an untested drug could redefine breast cancer care—or backfire. Why Novartis is banking on SNV4818's untapped potential before clinical trials even begin.
How prior authorization delays can harm patients and frustrate doctors
A system meant to cut costs is putting patients at risk. Doctors warn that insurance red tape is delaying care—and even forcing dangerous medication switches.